A Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 Ointment in Patients With Postherpetic Neuralgia (PHN) ((PHN))
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (4% and 8% w/w Ointment) in Patients With Postherpetic Neuralgia.
Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
A PHASE2 clinical study on Postherpetic Neuralgia, this trial is completed. The trial is conducted by Teva Branded Pharmaceutical Products R&D, Inc. and has accumulated 15 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
15 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
▶ Show 10 earlier versions
-
Jun 2020 — Jan 2021 [monthly]
Completed PHASE2
-
May 2020 — Jun 2020 [monthly]
Completed PHASE2
-
Nov 2018 — May 2020 [monthly]
Completed PHASE2
-
Jun 2018 — Nov 2018 [monthly]
Completed PHASE2
-
May 2018 — Jun 2018 [monthly]
Completed PHASE2
-
Sep 2017 — May 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Apr 2017 — Jun 2017 [monthly]
Recruiting PHASE2
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Feb 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Teva Branded Pharmaceutical Products R&D, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .